

Stm 天主教聖馬爾定醫院

(一) 小細胞肺癌化療處方集

最初出版日期：99.01
最後更新日期：115.02

癌別：小細胞肺癌	
CCRT	<p>(1) Cisplatin 60 mg/m² (N/S 500 c.c.; ≥4hrs) + Etoposide 200-300 mg/m² (N/S 500 c.c.; ≥3rs,divided or single dose) q 4 wks (Cancer Treat. Rep.1979; 63:1593-7)</p> <p>(2) Cisplatin 60 mg/m² + Etoposide 200-300 mg/m² +Endoxan 600 mg/m² (N/S 300 c.c.; 2hrs) q 4 wks (JCO 1987 ; 5:1874-9) (R.R. :88%(C.R.:57%))</p>
Palliative	<p>(1) Cisplatin 60 mg/m² (N/S 500 c.c.; ≥4hrs) + Etoposide 200-300 mg/m² (N/S 500 c.c.; ≥3rs,divided or single dose) q 4 wks (Cancer Treat. Rep.1979; 63:1593-7)</p> <p>1). Atezolizumab 1200 mg + Etoposide + Carboplatin AUC=6 q3wk/cycle (112/12/1)</p> <p>2). Durvalumab 1500 mg + Etoposide + Cisplatin or Carboplatin (114/2/1)</p> <p>(2) Cisplatin 60 mg/m² + Etoposide 200-300 mg/m² +Endoxan 600 mg/m² (N/S 300 c.c.; 2hrs) q 4 wks (JCO 1987 ; 5:1874-9) (R.R. :88%(C.R.:57%))</p> <p>(3) *Irinotecan 140,150,160 mg/m² (N/S 500 c.c.; 3 hrs) + Etoposide 150 mg/m² (N/S 500 c.c.; ≥3hrs) q 2wks (for Cisplatin – resistant) (Oncology 2002 Apr.,16(4):419-25)</p> <p>(4) Topotecan 1, 1.2 mg/m² /d (N/S 100 c.c.,30 mins)* 3-5 days q 4 wks (for cisplatin – resistant, 2nd-line) (Drugs 1999 Sep;58(3):533-51)</p> <p>(5) Carboplatin (AUC 6) (N/S 500 cc; 6 hrs) + Etoposide 100 mg/m² (N/S 500 cc; 3hrs on D1-D3) (for CCr < 60)</p> <p>(6) Consider *Bevacizumab 5mg/kg/cycle (JCO, Nov. 2011 33:4436-4441)</p>

PD-L1 抑制劑 (如 atezolizumab、nivolumab、Pembrolizumab (1090401)、Durvalumab(1121201))

(二) 非小細胞肺癌化療處方集

最初出版日期：99.01

最後更新日期：115.02

癌別：非小細胞肺癌	
CCRT	(1) Cisplatin 60 mg/m ² (N/S 500 c.c.; ≥4hrs) q 4 wks + Vinorelbine (v.) 25-35 mg/m ² (N/S 50 c.c.; 10 mins) or (P.O.) 55-70 mg/m ² q 2 wks (JCO 1994; 12: 360-7) (2) Cisplatin 60 mg/m ² + Etoposide 200-300 mg/m ² (N/S 500 c.c.; ≥3rs, divided or single dose) q 4 wks (Cancer Treat. Rep. 1979; 63:1593-7)
Neoadjuvant(術前)	(1) Cisplatin 60 mg/m ² (N/S 500 c.c.; ≥4hrs) q 4 wks + Vinorelbine (v.) 25-35 mg/m ² (N/S 50 c.c.; 10 mins) or (P.O.) 55-70 mg/m ² q 2 wks (JCO 1994; 12: 360-7) (2) Cisplatin 60 mg/m ² q 4 wks + Gemcitabine 1000 mg/m ² (N/S 100 c.c.; 30 mins) q 2 wks (Annals of Oncology Vol.10 Feb 1999, pp 217-221) (JCO 1997; 15:744-9) (3) Cisplatin 60 mg/m ² q 4 wks + Docetaxel 35,40 mg/m ² (N/S 100 c.c.; 1 hr) q 2wks (Oncology Jul. 01, 1997) (4) Cisplatin 60 mg/m ² q 4 wks + Paclitaxel 85 mg/m ² (N/S 300 c.c.; 2 hrs) q 2 wks (JCO 1995; 13:1860-70) (5) Cisplatin 60 mg/m ² + Pemetrexed 500 mg/m ² (N/S 100 c.c.; 20 mins) q 4wks (for NSCLC 且 non-squamous cancer) (Annals of Oncology Vol.22 Nov. 2011, pp 2466-2470)
Adjuvant(術後)	Cisplatin 60 mg/m ² (N/S 500 c.c.; ≥4hrs) q 4 weeks + Vinorelbine (v.) 25-35 mg/m ² (N/S 50 c.c.; 10 mins) or (P.O.) 55-70 mg/m ² q 2 wks * 4 cycles
Palliative(無法手術)	(1) Cisplatin 60 mg/m ² (N/S 500 c.c.; ≥4hrs) q 4 wks + Vinorelbine (v.) 25-35 mg/m ² (N/S 50 c.c.; 10 mins) or (P.O.) 55-70 mg/m ² q 2 wks (JCO 1994; 12: 360-7) (2) Cisplatin 60 mg/m ² q 4 wks + Gemcitabine 1000 mg/m ² (N/S 100 c.c.; 30 mins) q 2 wks (Annals of Oncology Vol.10 Feb 1999, pp 217-221) (JCO 1997; 15:744-9) (3) Cisplatin 60 mg/m ² q 4 wks + Docetaxel 35,40 mg/m ² (N/S 100 c.c.; 1 hr) q 2wks (Oncology Jul. 01, 1997) (4) Cisplatin 60 mg/m ² q 4 wks + Paclitaxel 85 mg/m ² (N/S 300 c.c.; 2 hrs) q 2 wks (JCO 1995; 13:1860-70) (5) Cisplatin 60 mg/m ² + Pemetrexed 500 mg/m ² (N/S 100 c.c.; 20 mins) q 4wks (for NSCLC 且 non-squamous cancer) (Annals of Oncology Vol.22 Nov. 2011, pp 2466-2470) (6) Carboplatin(AUC:5-6) + Paclitaxel 85 mg/m ² (N/S 300 c.c.; 2 hrs) q 2 wks + pembrolizumab 200mg

癌別: 非小細胞肺癌

以上之化療處方用藥,若於 palliative use 可不合併 cisplatin

Besides, consider the following agents:

* Bevacizumab 5mg/kg/cycle (The Oncologist Aug 14, 2007)

* Gefitinib 250mg gd (健保條例)

* Erlotinib 150mg or 100mg gd (健保條例)

* Afatinib 40mg or 30mg gd (健保條例)

* Crizotinib 250 mg bid (健保條例)

* Ceritinib 750 mg qd (健保條例)

* Alectinib 600mg (with meals) bid (Cancer Cell Vol. 19 May 2011 pp 679-690)

* Ramucirumab 6,8mg/kg/dose (N/S 300c.c; 90mins) (approved by FDA on 4, 21, 2014) (Am Health Drug Benefits 2015, Mar; 8:49-53)

Immunotherapy: PD-1, PD-L1 抑制劑 (如 atezolizumab、nivolumab、Pembrolizumab、avelumab)(1091101) 、Durvalumab (1121201)

Brigatinib (如 Alunbrig) (1090801、1130601)

Osimerinib(Tagrisso) (1091001、1130601)

Tegafuar/ gimeacil / Oteracil 複方製劑(如 TS-1) 35 mg/m² on D1-D5,D8-D12, q4wk/cycle(1090201)

Entrectinib (如 Rozlytrek) : (1100701、1130601)

Lorlatinib(Lorviqua) (1090601、1121101、1130401、1130601)

Dabrafenib(Tafinlar) 、Trametinib (Mekinist)(1130301、1130601)

Erlotinib 150 mg qd + Bevacizumab(7.5mg/kg in N/S 100 ml run 20 mins, q3wk)(1130301)

Larotrectinib (NTRK fusion) (113/6/1)

Tepotinib (Met. exon 14)(113/6/1)

Amivantamab(exon 20ins.) + Pemetrexed + Carboplatin(1130601)

Durvalumab(1500 mg in N/S 100ml run 60 mins)(consolidation) q3wk, 12 個月(1140801).

Atezolizumab 1200mg (N/S 100 ml, 60mins) + Bevacizumab(15 mg/kg)(N/S 100ml, 20mins):

Paclitaxel 85 mg/m² on D1 D15

Carboplatin(AUC=5 or 6)(N/S 500 ml ,6 hrs)

Pembrolizumab monotherapy, 200mg in N/S 100ml, 60mins, q3wk x 2yr

Nivolumab monotherapy, 240mg in N/S 100ml, 60mins, q2wk x 2yr

Pembrolizumab + C/T(1140601、1140801):

- 1). For Squamous cell carcinoma: Paclitaxel 85 mg/m² on D1 D15 + Carboplatin(AUC=5 or 6)
- 2). For adenocarcinoma: Pemetrexed(限使用 Pexeda、Apeta 或 Pemetrexed Sandoz) + cisplatin